Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

1.010 +0.240 (+31.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,350,935
Open 0.7800
Bid (Size) 1.130 (3)
Ask (Size) 1.140 (5)
Prev. Close 0.7700
Today's Range 0.7800 - 1.020
52wk Range 0.7300 - 61.12
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
Via ACCESSWIRE
Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities
Via ACCESSWIRE

Performance

YTD
-84.61%
-84.61%
1 Month
-63.80%
-63.80%
3 Month
-86.12%
-86.12%
6 Month
-92.66%
-92.66%
1 Year
-97.53%
-97.53%

More News

Read More
Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug
Via ACCESSWIRE
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
Via Benzinga
Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases
Via ACCESSWIRE
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
Via ACCESSWIRE
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
Via ACCESSWIRE
Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
Via ACCESSWIRE
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
Via ACCESSWIRE
Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
7 F-Rated Stocks to Sell in February
Via InvestorPlace
Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
Via ACCESSWIRE
Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling
Via ACCESSWIRE
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
Via ACCESSWIRE
Here's Why Jaguar Health (JAGX) Stock Is Volatile Tuesday
Via Benzinga
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
Via ACCESSWIRE
Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
Via ACCESSWIRE
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dow Jumps Over 300 Points; Crude Oil Up 1%
Via Benzinga
Is Jaguar Health (JAGX) Stock Really Up 6,800%?
Via InvestorPlace
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views
Via Benzinga
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.